Cargando…

Dose‐dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity

AIMS: LIK066 (licogliflozin) is a dual sodium glucose co‐transporter 1/2 inhibitor with potential benefits in weight loss. This study evaluated the efficacy, tolerability and safety of licogliflozin in Japanese adults with obesity. MATERIALS AND METHODS: This study was a randomized, double‐blind, pl...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokote, Koutaro, Sano, Misako, Tsumiyama, Isao, Keefe, Deborah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328287/
https://www.ncbi.nlm.nih.gov/pubmed/32072763
http://dx.doi.org/10.1111/dom.14006
_version_ 1784757686616719360
author Yokote, Koutaro
Sano, Misako
Tsumiyama, Isao
Keefe, Deborah
author_facet Yokote, Koutaro
Sano, Misako
Tsumiyama, Isao
Keefe, Deborah
author_sort Yokote, Koutaro
collection PubMed
description AIMS: LIK066 (licogliflozin) is a dual sodium glucose co‐transporter 1/2 inhibitor with potential benefits in weight loss. This study evaluated the efficacy, tolerability and safety of licogliflozin in Japanese adults with obesity. MATERIALS AND METHODS: This study was a randomized, double‐blind, placebo‐controlled, dose‐finding study to evaluate the effect of licogliflozin (2.5, 10, 25 and 50 mg once daily) in 126 Japanese patients with obesity. The primary objective was to examine the dose–response relationship of licogliflozin treatment in body weight reduction relative to placebo at 12 weeks. The secondary objectives included assessment of responder rates, change in parameters related to complications, visceral and subcutaneous fat area, and safety during 12 weeks of treatment. RESULTS: The placebo‐subtracted least square mean percentage change in body weight from baseline at week 12 was −1.99 (95% confidence interval −2.92, −0.21), −3.00 (−4.15, −1.70), −3.54 (−4.54, −2.26) and − 3.91% (−5.01, −2.77) in licogliflozin 2.5, 10, 25 and 50 mg once‐daily dose groups, respectively. The proportion of responders with ≥3% reduction in body weight in the licogliflozin 2.5, 10, 25 and 50 mg once‐daily dose groups were 15.8%, 55.6%, 50.0% and 56.7%, respectively, versus placebo [7.1%; P ≤0.002 for all except the 2.5 mg once‐daily group (P = 0.39)]. Dose‐dependent reductions were observed significantly in haemoglobin A1c, uric acid, fasting plasma glucose and potentially in the waist circumference, diastolic blood pressure and visceral fat area. CONCLUSION: Dual inhibition of SGLT1/2 with licogliflozin treatment induced a dose‐dependent reduction in body weight in Japanese patients with obesity. Treatment with licogliflozin was safe and well tolerated in this study. The study is registered with ClinicalTrials.gov (NCT03320941).
format Online
Article
Text
id pubmed-9328287
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-93282872022-07-30 Dose‐dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity Yokote, Koutaro Sano, Misako Tsumiyama, Isao Keefe, Deborah Diabetes Obes Metab Original Articles AIMS: LIK066 (licogliflozin) is a dual sodium glucose co‐transporter 1/2 inhibitor with potential benefits in weight loss. This study evaluated the efficacy, tolerability and safety of licogliflozin in Japanese adults with obesity. MATERIALS AND METHODS: This study was a randomized, double‐blind, placebo‐controlled, dose‐finding study to evaluate the effect of licogliflozin (2.5, 10, 25 and 50 mg once daily) in 126 Japanese patients with obesity. The primary objective was to examine the dose–response relationship of licogliflozin treatment in body weight reduction relative to placebo at 12 weeks. The secondary objectives included assessment of responder rates, change in parameters related to complications, visceral and subcutaneous fat area, and safety during 12 weeks of treatment. RESULTS: The placebo‐subtracted least square mean percentage change in body weight from baseline at week 12 was −1.99 (95% confidence interval −2.92, −0.21), −3.00 (−4.15, −1.70), −3.54 (−4.54, −2.26) and − 3.91% (−5.01, −2.77) in licogliflozin 2.5, 10, 25 and 50 mg once‐daily dose groups, respectively. The proportion of responders with ≥3% reduction in body weight in the licogliflozin 2.5, 10, 25 and 50 mg once‐daily dose groups were 15.8%, 55.6%, 50.0% and 56.7%, respectively, versus placebo [7.1%; P ≤0.002 for all except the 2.5 mg once‐daily group (P = 0.39)]. Dose‐dependent reductions were observed significantly in haemoglobin A1c, uric acid, fasting plasma glucose and potentially in the waist circumference, diastolic blood pressure and visceral fat area. CONCLUSION: Dual inhibition of SGLT1/2 with licogliflozin treatment induced a dose‐dependent reduction in body weight in Japanese patients with obesity. Treatment with licogliflozin was safe and well tolerated in this study. The study is registered with ClinicalTrials.gov (NCT03320941). Blackwell Publishing Ltd 2020-03-12 2020-07 /pmc/articles/PMC9328287/ /pubmed/32072763 http://dx.doi.org/10.1111/dom.14006 Text en © 2020 Novartis Pharma K.K. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Yokote, Koutaro
Sano, Misako
Tsumiyama, Isao
Keefe, Deborah
Dose‐dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity
title Dose‐dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity
title_full Dose‐dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity
title_fullStr Dose‐dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity
title_full_unstemmed Dose‐dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity
title_short Dose‐dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity
title_sort dose‐dependent reduction in body weight with lik066 (licogliflozin) treatment in japanese patients with obesity
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328287/
https://www.ncbi.nlm.nih.gov/pubmed/32072763
http://dx.doi.org/10.1111/dom.14006
work_keys_str_mv AT yokotekoutaro dosedependentreductioninbodyweightwithlik066licogliflozintreatmentinjapanesepatientswithobesity
AT sanomisako dosedependentreductioninbodyweightwithlik066licogliflozintreatmentinjapanesepatientswithobesity
AT tsumiyamaisao dosedependentreductioninbodyweightwithlik066licogliflozintreatmentinjapanesepatientswithobesity
AT keefedeborah dosedependentreductioninbodyweightwithlik066licogliflozintreatmentinjapanesepatientswithobesity